Antibe Therapeutics Inc.
ATE
Rang în acțiuni
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Preț acțiune
$0.21483059
Ultima sincronizare: 2024-05-07
Capitalizare de piață
$11.13M
Schimbare (1 zi)
0.34%
Schimbare (1 an)
-0.36%
Țară
CA
Tranzacționează Antibe Therapeutics Inc. (ATE)
Categorie
Healthcare
Raport P/B pentru Antibe Therapeutics Inc. (ATE)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Antibe Therapeutics Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Antibe Therapeutics Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 3.5116 | - |
US
|
|
| 2.0146 | - |
IE
|
|
| 4.5025 | - |
US
|
|
| 2.5486 | - |
US
|
|
| - | - |
DE
|
